Abstract: There is provided a method of promoting neurogenesis by administering a therapeutic amount of a nitric oxide donor compound to a patient in need of neurogenesis promotion. Also provided is a compound for providing neurogenesis having an effective amount of a nitric oxide donor sufficient to promote neurogenesis. A nitric oxide compound for promoting neurogenesis is also provided. Further, a method of augmenting the production of brain cells and facilitating cellular structural and receptor changes by administering an effective amount of a nitric oxide donor compound to a site in need of augmentation is provided. There is provided a method of increasing both neurological and cognitive function by administering an effective amount of a nitric oxide donor compound to a patient.
Abstract: Mitigating radiation induced injury to a mammal that has been exposed to radiation by administering a pharmaceutically effective amount of a composition comprising at least one CXCR4 antagonist to the mammal.
Type:
Application
Filed:
October 28, 2010
Publication date:
February 14, 2013
Applicant:
HENRY FORD HEALTH SYSTEM
Inventors:
Jae Ho Kim, Stephen L. Brown, Andrew Kolozsvary
Abstract: A method of detecting a dislodged needle in a hemodialysis procedure includes measuring venous drip pressure of the dialysis machine of a patient undergoing hemodialysis, analyzing the venous drip pressure and deriving intravascular blood pressure at a location of venous needle insertion into the patient, comparing the derived intravascular blood pressure to a standard, repeating the measuring, analyzing and deriving, and comparing steps and, if the intravascular blood pressure is within a specified range of the standard, determining that a needle has been dislodged in the hemodialysis procedure. A method of alerting the patient and medical personnel of a dislodged needle in a hemodialysis procedure includes detecting a drop in intravascular pressure derived from measured venous drip pressure, determining that a needle is dislodged, and alerting medical personnel of the dislodged needle.
Type:
Grant
Filed:
September 29, 2009
Date of Patent:
January 8, 2013
Assignee:
Henry Ford Health System
Inventors:
Stanley Frinak, Gerard Zasuwa, Jerry Yee, Anatole Besarab
Abstract: The present invention includes a comprehensive replacement fluid system and method for the delivery of regional citrate anticoagulation (RCA) to extracorporeal blood circuits, wherein the system may include an online clearance monitor (OCM) and a circuit effluent online sensor system (OSS) for the continuous determination of patient plasma content of ultrafilterable solutes.
Type:
Application
Filed:
June 20, 2012
Publication date:
October 18, 2012
Applicant:
HENRY FORD HEALTH SYSTEM
Inventors:
Balazs Szamosfalvi, Stanley Frinak, Jerry Yee
Abstract: The present invention relates to a treatment of an autoimmune demyelinating disease/disorder. Also included in the present invention is the use of bone marrow stromal cells for the treatment of multiple sclerosis (MS).
Abstract: The present invention includes a comprehensive replacement fluid system and method for the delivery of regional citrate anticoagulation (RCA) to extracorporeal blood circuits, wherein the system may include an online clearance monitor (OCM) and a circuit effluent online sensor system (OSS) for the continuous determination of patient plasma content of ultrafilterable soultes.
Type:
Grant
Filed:
February 22, 2007
Date of Patent:
July 3, 2012
Assignee:
Henry Ford Health System
Inventors:
Balazs Szamosfalvi, Stanley Frinak, Jerry Yee
Abstract: The present invention includes a comprehensive replacement fluid system and method for the delivery of regional citrate anticoagulation (RCA) to extracorporeal blood circuits, wherein the system may include an online clearance monitor (OCM) and a circuit effluent online sensor system (OSS) for the continuous determination of patient plasma content of ultrafilterable solutes.
Type:
Application
Filed:
February 14, 2012
Publication date:
June 14, 2012
Applicant:
HENRY FORD HEALTH SYSTEM
Inventors:
Balazs Szamosfalvi, Stanley Frinak, Jerry Yee
Abstract: The present invention relates to a treatment of an autoimmune demyelinating disease/disorder. Also included in the present invention is the use of bone marrow stromal cells for the treatment of multiple sclerosis (MS).
Abstract: The present invention includes a comprehensive replacement fluid system and method for the delivery of regional citrate anticoagulation (RCA) to extracorporeal blood circuits, wherein the system may include an online clearance monitor (OCM) and a circuit effluent online sensor system (OSS) for the continuous determination of patient plasma content of ultrafilterable solutes.
Type:
Grant
Filed:
July 27, 2007
Date of Patent:
March 13, 2012
Assignee:
Henry Ford Health System
Inventors:
Balazs Szamosfalvi, Stanley Frinak, Jerry Yee
Abstract: A method for assessing whether a patient is at risk of developing a clinical condition includes receiving training data representing a set of patient-related variables for each of a plurality of patients; generating model data based on the received training data; receiving target data representing the set of patient-related variables for a target patient; determining a risk level for the target patient of developing the clinical condition; and indicating the risk level of the target patient, where the set of patient-related variables consists of a first set of variables when the clinical condition is a mortality condition and a second set of variables when the clinical condition is a morbidity condition.
Type:
Application
Filed:
October 5, 2011
Publication date:
March 8, 2012
Applicants:
Henry Ford Health System, THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Abstract: Capsules, emplacement apparatus, and associated methods for establishing a capsule within tissue are described herein. The emplacement apparatus may be catheter-based or implemented in a handheld unit. The emplacement apparatus serves to introduced an encapsulating membrane in a collapsed condition into the tissue, and then to expand the encapsulating membrane within the tissue into a capsule by injection of fill material into the encapsulating membrane. Other than being capable of injection through the emplacement apparatus, the fill material may be selected and formulated to achieve such mechanical and biological properties within the encapsulating membrane after injection as are desired to achieve the therapeutic effect sought for the patient. Mechanically, the fill material within the encapsulating membrane after injection may be a liquid, a semi-solid such as a gel, or a solid such as a cross-linked polymer. The fill material may or may not be sealed within the encapsulating membrane.
Type:
Application
Filed:
September 4, 2009
Publication date:
February 16, 2012
Applicants:
HENRY FORD HEALTH SYSTEM, CARDIOPOLYMERS, INC.
Inventors:
Frank Ahmann, Hani Sabbah, Donald Shannon
Abstract: Methods, systems and compositions comprising novel peptidomimetics are disclosed that can be used to inhibit calpain and, more specifically, to treat tissue damage caused by pathologic activation of calpains.
Abstract: Thymosin ?4 can be used to treat neuronal and brain injuries that are accompanied by neuronal cell death or injury, including injuries caused by stroke or trauma and injuries caused by neurological and neurodegenerative disease. In particular, stroke and multiple sclerosis are examples of conditions which may be ameliorated by treatment with thymosin ?4. Thymosin ?4 has been found to restore neurological tissue through several effects on several neurological parameters which are improved by administration of thymosin ?4 to a subject in need of neurological tissue restoration. For example, thymosin ?4 improves axonal myelination, migration of neural progenitor cells, neural progenitor cell proliferation, differentiation of neural progenitor cells into mature neurons, differentiation of neural progenitor cells into mature glia, nerve regeneration, and brain remodeling at locations of brain injury.
Type:
Application
Filed:
March 26, 2010
Publication date:
January 26, 2012
Applicant:
Henry Ford Health System
Inventors:
Michael Chopp, Zhenggang Zhang, Daniel C. Morris
Abstract: A method for providing a personalized health risk of a patient includes receiving training data corresponding to a plurality of patients and target data corresponding to a target patient; generating model data based on the training data according to an anomaly detection method; either determining whether the target data is anomalous with respect to the training data, or determining the extent to which the target data is anomalous with respect to the training data; and either indicating whether the target patient is at risk of the adverse outcome, or indicating the extent to which the target patient is at risk of the adverse outcome.
Type:
Application
Filed:
June 15, 2011
Publication date:
December 15, 2011
Applicants:
Henry Ford Health System, The Regents of the University of Michigan
Abstract: The present invention relates to a treatment of an autoimmune demyelinating disease/disorder. Also included in the present invention is the use of bone marrow stromal cells for the treatment of multiple sclerosis (MS).
Abstract: The present invention provides novel methods and compositions for the treatment of injuries to the mammalian central nervous system. These methods involve administering stromal cells in combination with a blood-brain barrier permeabilizing agent in order to enhance neurorestoration, functional neurological recovery, stromal cell engraftment, and treatment of neurodegenerative diseases.
Abstract: Structurally supportive material is implanted or injected into cardiac veins as discrete masses at various sites in the cardiac venous system to reinforce the myocardium for the purpose of preventing, moderating, stopping or reversing negative cardiac remodeling due to various adverse cardiac conditions, both acute and chronic, or for the purpose of treating localize anomalies of the heart, or for both purposes. The sites may be arranged in a pattern about one or more chambers of the heart such that the masses cooperatively reduce stress in the chamber wall and reduce chamber size. Some patterns also cause a beneficial global reshaping of the chamber. These changes occur quickly and are sustainable, and have a rapid and sustainable therapeutic effect on cardiac function.
Abstract: Structurally supportive material is implanted or injected into cardiac veins as discrete masses at various sites in the cardiac venous system to reinforce the myocardium for the purpose of preventing, moderating, stopping or reversing negative cardiac remodeling due to various adverse cardiac conditions, both acute and chronic, or for the purpose of treating localize anomalies of the heart, or for both purposes. The sites may be arranged in a pattern about one or more chambers of the heart such that the masses cooperatively reduce stress in the chamber wall and reduce chamber size. Some patterns also cause a beneficial global reshaping of the chamber. These changes occur quickly and are sustainable, and have a rapid and sustainable therapeutic effect on cardiac function.
Abstract: The present invention comprises methods and systems for treating a cardiac arrhythmia in a mammal by administering gated or pulsed radiofrequency current or other ablative energy to the mammal during one or more time periods of increased coronary blood flow. Preferred embodiments of the invention comprise, without limitation, the gated or pulsed administration of radiofrequency current in association with the formation of the dicrotic notch in the arterial blood pressure curve of the mammal. In accordance with the invention, the thermal effects of ablative energy application on the coronary artery are avoided or mitigated due to rapid coronary blood flow resulting in heat loss and minimization of damage to blood vessels.
Abstract: The invention comprises a novel virus that can kill mammalian cancer cells efficiently. The virus produces a novel protein that converts two non-toxic prodrugs into potent chemotherapeutic agents. These chemotherapeutic agents are produced locally and help the virus kill the cancer cells as well as sensitize them to radiation. In preclinical studies, the virus has proven effective at killing a variety of mammalian cancer cells either alone or when combined with prodrug therapy and/or radiation therapy. The invention may provide a safe and effective treatment for human cancer.
Type:
Grant
Filed:
January 30, 2006
Date of Patent:
October 19, 2010
Assignee:
Henry Ford Health System
Inventors:
Svend O. Freytag, Jae Ho Kim, Ken Barton, Dell Paielli